PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredients: Trenbolone Acetate (75 mg/ml), Drostanolone Propionate (50 mg/ml), Testosterone Propionate (100 mg/ml) — Total Strength: 225 mg/ml
Pharmacological Class: Synthetic Triple-Component Anabolic-Androgenic Steroid Blend ($19\text{-nor}$, DHT Derivative & Short-Ester Testosterone)
This multi-component injectable formulation by Bioniche Pharma combines three synergistic short-esterified androgenic and anabolic steroids: Trenbolone Acetate, Drostanolone Propionate, and Testosterone Propionate. Engineered by Bioniche Pharma to optimize anabolic potency, cellular nitrogen retention, and rapid tissue restoration, this fast-acting combination accelerates muscle recovery and counters catabolic wasting when supported by adequate dietary intake of protein and calories.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
The active constituents in Bioniche Pharma's triple blend work concurrently through high-affinity binding to androgen receptors to drive cellular protein synthesis and suppress catabolic pathways. Exogenous administration supports the maintenance and expansion of male sexual characteristics (maturation of the prostate, seminal vesicles, penis, and scrotum; male hair distribution; laryngeal expansion; and lean muscle accretion). Systemically, this combination promotes renal preservation of nitrogen, sodium, potassium, and phosphorus while suppressing urinary calcium excretion, yielding a strongly positive metabolic balance.
INDICATIONS & CLINICAL USE
- Therapeutic stimulation of tissue regeneration, protein anabolism, and cellular preservation in undernourished, debilitated, or severely catabolic patients.
- Adjunctive clinical management of cachexia, severe muscle atrophy, and involuntary weight loss associated with HIV wasting syndrome and other chronic systemic diseases.
CONTRAINDICATIONS
- Male patients with confirmed or suspected carcinoma of the prostate gland or male breast cancer.
- Female breast carcinoma complicated by severe hypercalcemia (elevated serum calcium levels).
- Patients with severe kidney disease, advanced renal failure, or severe hepatic impairment.
- Pregnancy and lactation due to severe risks of fetal harm, malformation, and endocrine disruption.
- Known hypersensitivity to Trenbolone Acetate, Drostanolone Propionate, Testosterone Propionate, carrier oils, or inactive components in Bioniche Pharma products.
PRECAUTIONS & METABOLIC MONITORS
- Glycemic Control: Anabolic steroids can alter insulin sensitivity and peripheral glucose clearance. Diabetic patients taking Bioniche Pharma products should perform routine blood or urine glucose monitoring, as antidiabetic medication dosages may require adjustment.
- Pediatric Caution & Skeletal Growth: Contraindicated in children and adolescents under 18 years of age due to risks of premature epiphyseal plate closure, stunted linear growth, and abnormal sexual development. Periodic bone age radiographies are required if administered under special medical conditions.
- Cardiovascular & Hepatic Surveillance: Regular monitoring of hepatic transaminases, serum lipid profiles (LDL elevation and HDL reduction), hematocrit/hemoglobin levels, and blood pressure is mandatory during therapy.
ADVERSE REACTIONS
- Endocrine & Reproductive: Suppression of endogenous pituitary-gonadal axis, oligospermia, testicular atrophy, impotence, priapism (painful, prolonged erections), and potential gynecomastia or progestational side effects.
- Dermatological & Androgenic: Severe acne vulgaris, oily skin, accelerated male pattern baldness (androgenetic alopecia), and body hair shifts.
- Gastrointestinal, CNS & Respiratory: Diarrhea, mood shifts, anxiety, insomnia or sleep disturbances, headache, dyspnea (breathing difficulties), rapid fluid retention leading to peripheral edema, and cardiovascular stress.
DOSAGE & ADMINISTRATION
Bioniche Pharma triple-component blend is formulated strictly for deep intramuscular injection. Due to the rapid pharmacokinetic profiles of the short acetate and propionate esters, administration must be frequent to maintain stable serum hormone concentrations:
- Therapeutic Schedule: Injections are typically administered 2 to 3 times per week. The total weekly dosage generally ranges between 450 mg and 675 mg (2 ml to 3 ml total weekly volume), precisely tailored to patient condition, tolerance, and medical supervision.
- Restriction: Not recommended for use in women or pediatric patients.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place away from direct light exposure, excess heat, and freezing temperatures. Keep strictly out of reach and sight of children.